94% of the Claims Were Found to be Novel
RA'ANANA, Israel, Feb. 14,
2024 /PRNewswire/ -- Inspira™ Technologies OXY
B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the
"Company" or "Inspira Technologies"), is a breakthrough medical
technology company targeting to supersede mechanical ventilators,
has received the first ever U.S. Patent approval for an orbiting
blood oxygenation delivery system, a core technology of the
revolutionary INSPIRA™ ART500 device. This innovation has 16 claims
found to be novel.
The orbiting blood oxygenation delivery system (VORTX™) is
designed to oxygenate blood without fiber membranes, and we believe
it is expected to revolutionize the medical landscape. The current
fiber technologies used for blood oxygenation cause substantial
damage to the patient's blood cells. Unlike the natural laminar
blood flow in blood vessels inside the body, in existing fiber
oxygenators, the blood is "forced" to flow in a harmful turbulent
flow through many layers of fibers while experiencing friction and
shear forces within the fiber walls. Since the fiber fabric is a
significant resistor to blood flow, high-pressure differences are
formed and cause significant damage to the various blood
components, including, high hemolysis (breakdown of red cells),
damage to white blood cells, activation of the inflammatory system
in the body, activation of the immune system, and blood
clotting.
We believe that the orbiting blood oxygenation delivery system
is another potentially game-changing core technology of the INSPIRA
ART500 device, in targeting the $19
billion mechanical ventilation market.
The INSPIRA ART500 is a breakthrough device, designed to empower
breathing in patients that are awake, by continuously measuring the
patient's blood parameters in real-time, and delivering needed
oxygen volume straight into the blood. As the INSPIRA ART500 is to
be equipped with the HYLA blood sensor, it is being designed to
continuously scan the patient's blood, potentially allowing for
real-time detection of changes in patient condition and providing
physicians with decision-supportive data.
CEO of Inspira Technologies Dagi Ben-Noon: "We believe that this
is a monumental advancement in the landscape of blood oxygenation
technologies and a pivotal milestone and another key indicator of
the INSPIRA ART500's core technological portfolio."
Inspira Technologies OXY B.H.N. Ltd.
Inspira™ Technologies is an innovative medical technology
company in the respiratory treatment arena. The Company has
developed a breakthrough Augmented Respiration Technology (INSPIRA
ART), designed to rebalance patient oxygen saturation levels. This
technology potentially allows patients to remain awake during
treatment while reducing the need for highly invasive, risky, and
costly mechanical ventilation systems that require intubation and
medically induced coma. The Company's products have not yet been
tested or used in humans and has not been approved by any
regulatory entity. For more information, please visit our
corporate website: https://inspira-technologies.com.
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking
statements pursuant to U.S. Federal securities laws. These
forward-looking statements and their implications are based on the
current expectations of the management of the Company only and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. For example, the Company is using
forward-looking statements when it discusses intended benefits and
uses of its technology, that its technology has the potential to
revolutionize the medical landscape, the target market for its
product, the potential of its products to allow for real-time
detection and the belief that the patent approval is a monumental
advancement in the landscape of blood oxygenation technologies.
These forward-looking statements and their implications are based
solely on the current expectations of the Company's management and
are subject to a number of factors and uncertainties that could
cause actual results to differ materially from those described in
the forward-looking statements. Except as otherwise required by
law, the Company undertakes no obligation to publicly release any
revisions to these forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. More detailed information about the risks and
uncertainties affecting the Company is contained under the heading
"Risk Factors" in the Company's annual report on Form 20-F for the
fiscal year ended December 31, 2022
filed with the U.S. Securities and Exchange Commission (the "SEC"),
which is available on the SEC's website, www.sec.gov.
Copyright © 2018-2024 Inspira Technologies OXY B.H.N. LTD. All
rights reserved.
Logo:
https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg
For more details:
Adi Shmueli
Public Relations Manager
Inspira Technologies
info@inspirao2.com
+972-9-9664485
View original
content:https://www.prnewswire.com/news-releases/inspira-receives-first-ever-us-patent-approval-for-an-orbiting-blood-oxygenation-delivery-system-302061765.html
SOURCE Inspira Technologies